BCCRC reports efficacy results of HER2+ breast cancer treatment to Bioasis

The additional studies extended earlier data where BT2111, a conjugate made up of biOasis Transcend vector and trastuzumab (Herceptin), a humanized monoclonal antibody, demonstrated increased ability to kill a HER2+ breast cancer cell line when compared to trastuzumab alone.

Bioasis CEO Rob Hutchison said the initial BT2111 study results by BCCRC compelled them to conduct additional work to confirm the initial findings.

"As further support we also undertook preliminary confocal imaging at the James Hogg Research Centre of brain sections taken from animals that were administered BT2111 intravenously," Hutchison added.